Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: A new treatment approach for B-cell non-Hodgkin's lymphoma

Medicine & Life Sciences

• ibritumomab tiuxetan 100%
• Radioimmunotherapy 84%
• B-Cell Lymphoma 62%
• Non-Hodgkin's Lymphoma 57%
• Rituximab 39%
• Yttrium-90 17%
• Therapeutics 9%
• Yttrium Radioisotopes 9%
• Platelet Count 7%
• Cold Temperature 7%
• Antibodies 6%
• Appointments and Schedules 6%
• Outpatients 6%
• Stem Cells 5%
• Indium-111 5%
• Pentetic Acid 5%
• Clinical Trials 5%
• Maximum Tolerated Dose 4%
• Chelating Agents 4%
• Thrombocytopenia 3%
• Anti-Idiotypic Antibodies 3%
• Intercellular Signaling Peptides and Proteins 3%
• Radiation 3%
• Monoclonal Antibodies 2%
• Safety 2%
• Neoplasms 1%